Partner Rare

CRACKING THE EMA CODE

Expanding into Europe

Article 1

www.partner-rare.com

Partner Rare

Expanding a Rare Disease drug's marketing authorization into Europe can potentially increase a company's net worth, but it's not a guaranteed outcome. Here's a breakdown of the factors involved

Potential Benefits

Increased Market Size

Europe represents a significant market with a large population. Expanding authorization allows the company to access a wider patient base, potentially leading to increased patients, data, reputation, and revenue.

Stability

While FDA approval is a crucial step, established healthcare payor systems in Europe offer a more comprehensive approach for Rare Disease drugs. They provide a clearer path to patient access and reimbursement, leading to greater stability for pharmaceutical companies developing these life-saving treatments. This stability allows companies to further invest in research and development, ultimately benefiting patients with Rare Diseases.

Enhanced Brand Reputation

Successfully navigating the European regulatory process and entering a new market can enhance the company's reputation as a leader in Rare Disease treatment. This can attract investors and potentially increase share prices.

Partner Rare

Potential Challenges

Regulatory Costs

Obtaining marketing authorization in Europe involves additional costs for compliance, clinical trials, and regulatory fees.

Competition

The company might face competition from existing treatments or drugs in development within the European market, but in the Rare Disease field this is generally unlikely.

Market Access Hurdles

Negotiating reimbursement with European healthcare systems can be complex and time-consuming, delaying the drug's impact on revenue.

Overall Impact

The net effect on a company's net worth depends on a variety of factors

- Market size and potential drug sales in Europe
- Development and regulatory costs
- Pricing strategy and reimbursement negotiations
- Competition in the European market

Partner Rare

Some Additional Points To Consider

HTA considers the drug's clinical value, cost-effectiveness, and budgetary impact on the healthcare system.

The specific disease the drug targets plays a role. A drug for a highly unmet medical need might see faster regulatory approval, adoption, and higher pricing in Europe.

The European payor systems involve a multi-step process that includes both regulatory approval (similar to FDA) and health technology assessment (HTA).

If a drug demonstrates strong clinical benefit and cost-effectiveness, established payor systems in Europe are more likely to provide reimbursement, ensuring wider patient access and a more predictable revenue stream for the company.

Expanding a rare disease drug's authorization into Europe can be a significant strategic move with the potential to increase a company's net worth. However, it's crucial to carefully assess the costs, competition, and market dynamics to ensure a positive return on investment.

Partner Rare

How Partner Rare Can Help You Navigate European Expansion for Your Rare Disease Drug

Expanding a rare disease drug's marketing authorization into Europe presents exciting opportunities, but also complex challenges.

Partner Rare's highly experienced and specialized team of strategic advisors and consultants can help you navigate this process and maximize your chances of success.

Partner Rare

Here's How We Can Support Your European Expansion

Regulatory Expertise

Our team has deep knowledge of the European regulatory landscape, including EMA requirements and national variations. We can guide you through the entire authorization process, minimizing delays and ensuring compliance.

Market Access Strategy

We will work closely with you to develop a comprehensive market access strategy tailored to the European market. This includes identifying key stakeholders, pricing, and reimbursement negotiations, and developing patient advocacy initiatives.

Partnership Development

Our extensive network within the European Rare Disease community can connect you with potential partners. This can include collaborations with patient advocacy groups, research institutions, and potential distributors.

Financial Considerations

We can help you develop a cost-effective approach to your European expansion, considering regulatory fees, pricing strategies, and potential funding opportunities.

Partner Rare

Expert Legal Counsel

Partner Rare offers a one-stop shop for navigating the complex European market for Rare Disease treatments. Leveraging our extensive experience within the European life sciences sector, our integrated legal and consulting services seamlessly support you from strategic planning to daily operations.

This includes expert legal counsel on everything from product development to market access, with a focus on intellectual property rights. We also provide operational support such as business entity setup, HR solutions, and pharmacovigilance. Our team of legal and business experts, with vast experience in Mergers and Acquisitions, ensures a smooth and compliant market entry, maximizing your potential to reach patients.



Building Trust and Maximizing Impact in the European Rare Disease Market

Leveraging our deep expertise in Rare Disease development and European market access, Partner Rare can be your trusted partner for a successful European launch. We'll guide you through every step, ensuring patients gain access to the life-saving therapies they need.

But our commitment goes beyond launch. We work diligently to build your company's reputation among key stakeholders – healthcare professionals (HCPs), patient organizations, patients themselves, and the European Medicines Agency (EMA).

This collaborative approach fosters trust and ensures a smooth, compliant market entry. Ultimately, by maximizing patient access and building a strong reputation, Partner Rare helps you achieve your goals and increase your company's net worth.

About the Author

Professor Trevor Jones is a seasoned leader in the pharmaceutical and biotechnology industries, currently serving as Chairman of e-Therapeutics plc and Director of Techimmune LLC and Ascension Healthcare plc.

With over four decades of experience, his expertise spans drug discovery, research and development, regulatory affairs, and commercialization. He has held senior positions at leading companies like Allergan and The Wellcome Foundation, and served as Director General of the ABPI.

Professor Jones is a recognized expert in malaria research and a recipient of numerous honorary degrees and Gold Medals.

His commitment to public service is evident through his involvement with various government advisory bodies, including the UK Medicines Commission, the World Health Organisation, and the EU Commission.

To leverage Professor Jones's vast experience and insights for your organization, contact Partner Rare for a complimentary consultation.


Partner
Rare